Optical/Ophthalmic
Press Release: AcuFocus small-aperture IOL receives CE Mark for Europe
Irvine, CA – AcuFocus, Inc. (www.acufocus.com), the global leader in small-aperture technology, today announced that its extended depth of focus intraocular lens (IOL), the IC-8™ small aperture IOL, has achieved CE Mark (Conformité Européenne) approval in Europe. The lens is designed to provide exceptional visual quality across a broad range of vision for presbyopic patients with cataracts.
Vision: AcuFocus lands E.U. approval for next-gen eye implant
California-based device maker AcuFocus is taking its next-generation intraocular lens to Europe after winning regulatory approval to treat cataract patients with near vision loss, or presbyopia.
Abbott puts $60M in Malaysia
Avedro picks up Swiss eye firm
Avedro said today that it augmented its corneal cross-linking capabilities with the acquisition of a Swiss ophthalmology firm, Iroc Innocross AG, for an unspecified amount.
AcuFocus adds $21M for Kamra presbyopia inlay
AcuFocus said today that it raised another $21 million in an oversubscribed round as it awaits a decision from the FDA on its Kamra device, a corneal inlay designed to treat near vision loss, or presbyopia.
Second Sight Medical lands French funding for ‘bionic eye’
Second Sight Medical announced this week that it landed a financial contract with the French Ministry of Health to provide funding for the 1st wave of patients in the country to receive treatment with the Argus II vision system.
FDA delays UDI rule for contacts, intraocular lenses
Makers of contact lenses and intraocular lenses are getting a 1-year reprieve after the FDA agreed to shift their due date for complying with Unique Device Identifier rules.
Manufacturers successfully lobbied for a delay after demonstrating that requirements for lenses would create a massive burden for both device makers and regulators.
Ocular Therapeutix IPO reaches $75M with over-allotment
Bedford, Mass.-based Ocular Therapeutix (NSDQ:OCUL) raised $74.8 million though its initial public offering after underwriters fully exercised an over-allotment option to snag additional shares.
FDA denies ex-staffer’s Lasik petition
‘Bionic eye’ maker Second Sight files for $32M IPO
Second Sight Medical hopes to raise $32 million through an initial public offering in support of its wearable visual prosthetics.
The company plans to offer shares at $9 apiece, saying it’ll used the proceeds from its IPO to boost sales & marketing, seek regulatory approvals in new regions and work on the next generation of its technology for helping restore vision to the blind.